Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates

Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys

(2015) Nicolas Morin et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Therapeutic potential of targeting glutamate receptors in Parkinson’s disease

(2014) Clare Finlay et al.   JOURNAL OF NEURAL TRANSMISSION

GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease

(2014) Xiaoqun Zhang et al.   JOURNAL OF NEUROCHEMISTRY

Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys

(2014) Nicolas Morin et al.   NEUROPHARMACOLOGY

Advances in non-dopaminergic treatments for Parkinson's disease

(2014) Sandy Stayte et al.   Frontiers in Neuroscience

Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia

(2013) Golnasim Riahi et al.   BIOCHEMICAL PHARMACOLOGY

Modeling dyskinesia in animal models of Parkinson disease

(2013) Nicolas Morin et al.   EXPERIMENTAL NEUROLOGY

Glycine site agonists of theN-methyl-d-aspartate receptor and Parkinson's disease: A hypothesis

(2013) Uriel Heresco-Levy et al.   MOVEMENT DISORDERS

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

(2013) Fabrizio Stocchi et al.   MOVEMENT DISORDERS

Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys

(2013) Nicolas Morin et al.   NEUROPHARMACOLOGY

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy

(2013) Fabrizio Gasparini et al.   Parkinsons Disease

Glutamate Receptors as Therapeutic Targets for Parkinsons Disease

(2012) Kari Johnson et al.   CNS & Neurological Disorders-Drug Targets

New pharmacological avenues for the treatment ofl-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

(2012) Fabio Blandini et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease

(2012) V. Bagetta et al.   JOURNAL OF NEUROSCIENCE

Effect of chronic l-DOPA treatment on 5-HT1A receptors in parkinsonian monkey brain

(2012) Golnasim Riahi et al.   NEUROCHEMISTRY INTERNATIONAL

MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates

(2012) Nicolas Morin et al.   NEUROPHARMACOLOGY

Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia

(2012) Khaled-Ezaheir Bennouar et al.   NEUROPHARMACOLOGY

Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesias

(2011) Golnasim Riahi et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia

(2011) Francesco Errico et al.   EXPERIMENTAL NEUROLOGY

Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation

(2011) Mahmoud M. Iravani et al.   JOURNAL OF NEURAL TRANSMISSION

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

(2011) Daniela Berg et al.   MOVEMENT DISORDERS

Priorities in Parkinson's disease research

(2011) Wassilios G. Meissner et al.   NATURE REVIEWS DRUG DISCOVERY

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys

(2011) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial

(2011) Hideyuki Sawada et al.   PLoS One

Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia

(2010) Daniella Rylander et al.   ANNALS OF NEUROLOGY

Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease

(2010) Colleen M. Niswender et al.   Annual Review of Pharmacology and Toxicology

Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease

(2010) Christopher Kobylecki et al.   JOURNAL OF NEUROCHEMISTRY

Effect of l-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys

(2010) Bazoumana Ouattara et al.   JOURNAL OF NEUROCHEMISTRY

Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

(2010) T. H. Johnston et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

(2010) Daniella Rylander et al.   NEUROBIOLOGY OF DISEASE

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys

(2010) Nicolas Morin et al.   NEUROPHARMACOLOGY

Antagonists at Metabotropic Glutamate Receptor Subtype 5

(2009) F. Ivy Carroll   Annals of the New York Academy of Sciences

Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients

(2009) Pershia Samadi et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

RTP801 Is Induced in Parkinson's Disease and Mediates Neuron Death by Inhibiting Akt Phosphorylation/Activation

(2009) C. Malagelada et al.   JOURNAL OF NEUROSCIENCE

Metabotropic Glutamate 7 Receptor Subtype Modulates Motor Symptoms in Rodent Models of Parkinson's Disease

(2009) B. Greco et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling

(2009) D. Rylander et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications

(2009) Bazoumana Ouattara et al.   NEUROBIOLOGY OF AGING

The scientific and clinical basis for the treatment of Parkinson disease (2009)

(2009) C. W. Olanow et al.   NEUROLOGY

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys

(2009) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys

(2009) Marc Morissette et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Inhibition of mTOR Signaling in Parkinson's Disease Prevents L-DOPA-Induced Dyskinesia

(2009) E. Santini et al.   Science Signaling

Receptor–receptor interactions within receptor mosaics. Impact on neuropsychopharmacology

(2008) K. Fuxe et al.   BRAIN RESEARCH REVIEWS

Treatment of levodopa-induced motor complications

(2008) Fabrizio Stocchi et al.   MOVEMENT DISORDERS

Molecular mechanisms of L-DOPA-induced dyskinesia

(2008) Peter Jenner   NATURE REVIEWS NEUROSCIENCE

Association between AKT1 gene and Parkinson's disease: A protective haplotype

(2008) Georgia Xiromerisiou et al.   NEUROSCIENCE LETTERS

Progress in Parkinson's disease—Where do we stand?

(2008) André Toulouse et al.   PROGRESS IN NEUROBIOLOGY

Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys

(2007) L GREGOIRE et al.   BEHAVIOURAL BRAIN RESEARCH

Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo

(2007) Nicholas MacInnes et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

(2007) Pershia Samadi et al.   NEUROBIOLOGY OF AGING

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

(2007) Giovanna Levandis et al.   NEUROBIOLOGY OF DISEASE